Globally, Tuberculosis (TB) is one of the leading prevalent illnesses. Researchers have been working efficiently to prevent TB in recent decades. The innate and adaptive immune mechanism of host are compromised by diabetes mellitus (DM), which reduces their ability to eradicate Mycobacterium tuberculosis (MTB) bacilli. This may significantly enhance the likelihood for contracting TB. The WHO has suggested a number of important intervention techniques to lessen this dual burden, most notably the creation of cooperative control programs, TB diagnosis and treatment in people with DM, as well as DM detection and treatment in patients with TB. The co-occurrence of DM and TB is an increasing worldwide health problem, therefore serving as the rationale for this study. As DM reaches epidemic proportions globally and TB remains a major infectious cause of death, their bidirectional relationship poses a critical public health concern. TB patients are more prone to diabetes because of their weakened immune systems, in accordance to numerous research findings. Angiogenesis-inflammation nexus indicators, such as elevated levels of circulating inflammatory cytokines along with an increase in inflammation, are distinctive characteristics of DM co-morbidity with TB. In an effort to lessen the collective impact of both illnesses, it would be crucial to develop logical treatment decisions by comprehending more about the immunological foundation of TB with DM susceptibility.